产品详情
文献和实验
相关推荐
RNAscope or BaseScope
Target Probes
Controls
Manual assays
Automated Assays
Accessories
Software
ACD——一个Bio-Techne品牌，通过释放RNA的力量，缩短了个性化医疗的道路，并使研究、药物开发和临床应用成为可能。ACD是分子病理学新兴领域的领*者，为个性化医疗开发基于细胞和组织的研究和诊断测试。
总部位于硅谷的ACD的产品和药物分析服务基于其专有的RNAscope®技术，这是第一个多重荧光和显色原位杂交平台，能够原位检测和定量RNA的单分子。ACD有两条产品线，即RNAscope®和BaseScope™ 除制药分析服务业务外，该业务还包括分析试剂盒和15000多个现成探针，允许客户快速运行针对其独特目标的分析。自2011年首次推出以来，这项技术拥有1200多条引文，现在每天都有一份新的出版物，用于单、双和多重RNA分析。
ACD的产品和服务基于其专有的RNAscope®技术，这是第一个能够以单分子灵敏度原位检测和量化RNA生物标记物的多重荧光和显色原位杂交平台。
除了持续努力开发用于癌症治疗的专有诊断测试外，ACD还与制药和生物技术公司建立伙伴关系，以验证用于靶向治疗开发的生物标记物。这些内部和外部努力将继续使ACD成为分子诊断和伴随诊断领域的领*者。
该公司的技术克服了用于辅助诊断的生物标志物识别和验证的关键障碍。ACD的RNAscope®平台提供了一种原位定位和测量RNA的新方法，具有极高的灵敏度、特异性和多重化能力。新检测的周转时间缩短为三周。这些优势使该技术成为解决患者和疾病异质性问题的有力工具，从而缩短了个性化医疗的道路。
ACD - a Bio-Techne brand, shortens the path to personalized medicine and enables research, drug development and clinical applications by unlocking the power of RNA. ACD is a leader in the emerging field of molecular pathology, developing cell- and tissue-based research and diagnostic tests for personalized medicine.
Based in Silicon Valley, ACD’s products and pharma assay services are based on its proprietary RNAscope® technology, the first multiplex fluorescent and chromogenic in situ hybridization platform, capable of detecting and quantifying single molecules of RNA in situ. ACD has two product lines, namely RNAscope® and BaseScope™ consisting of assay reagent kits and 15,000+ off-the-shelf probes in addition to a Pharma Assay Services business which allow customers to run assays for their unique targets rapidly. Since its first launch in 2011, the technology boasts 1200+ citations, a new publication each day now, for single, duplex and multiplex RNA analysis.
ACD’s products and services are based on its proprietary RNAscope® Technology, the first multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity.
In addition to its ongoing efforts to develop proprietary diagnostic tests for cancer management, ACD also establishes partnerships with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development. These internal and external efforts will continue to position ACD as a leader in molecular diagnostics and companion diagnostics.
The company’s technology overcomes critical hurdles in the identification and validation of biomarkers for companion diagnostics. ACD’s RNAscope® platform provides a new way of localizing and measuring RNA in situ with exceptional levels of sensitivity, specificity, and the ability to multiplex. Turnaround time for a new assay is reduced to three weeks. These advantages make the technology a powerful tool to address the issue of patient and disease heterogeneity, thus shortening the path to personalized medicine.
Target Probes
Controls
Manual assays
Automated Assays
Accessories
Software
ACD——一个Bio-Techne品牌，通过释放RNA的力量，缩短了个性化医疗的道路，并使研究、药物开发和临床应用成为可能。ACD是分子病理学新兴领域的领*者，为个性化医疗开发基于细胞和组织的研究和诊断测试。
总部位于硅谷的ACD的产品和药物分析服务基于其专有的RNAscope®技术，这是第一个多重荧光和显色原位杂交平台，能够原位检测和定量RNA的单分子。ACD有两条产品线，即RNAscope®和BaseScope™ 除制药分析服务业务外，该业务还包括分析试剂盒和15000多个现成探针，允许客户快速运行针对其独特目标的分析。自2011年首次推出以来，这项技术拥有1200多条引文，现在每天都有一份新的出版物，用于单、双和多重RNA分析。
ACD的产品和服务基于其专有的RNAscope®技术，这是第一个能够以单分子灵敏度原位检测和量化RNA生物标记物的多重荧光和显色原位杂交平台。
除了持续努力开发用于癌症治疗的专有诊断测试外，ACD还与制药和生物技术公司建立伙伴关系，以验证用于靶向治疗开发的生物标记物。这些内部和外部努力将继续使ACD成为分子诊断和伴随诊断领域的领*者。
该公司的技术克服了用于辅助诊断的生物标志物识别和验证的关键障碍。ACD的RNAscope®平台提供了一种原位定位和测量RNA的新方法，具有极高的灵敏度、特异性和多重化能力。新检测的周转时间缩短为三周。这些优势使该技术成为解决患者和疾病异质性问题的有力工具，从而缩短了个性化医疗的道路。
ACD - a Bio-Techne brand, shortens the path to personalized medicine and enables research, drug development and clinical applications by unlocking the power of RNA. ACD is a leader in the emerging field of molecular pathology, developing cell- and tissue-based research and diagnostic tests for personalized medicine.
Based in Silicon Valley, ACD’s products and pharma assay services are based on its proprietary RNAscope® technology, the first multiplex fluorescent and chromogenic in situ hybridization platform, capable of detecting and quantifying single molecules of RNA in situ. ACD has two product lines, namely RNAscope® and BaseScope™ consisting of assay reagent kits and 15,000+ off-the-shelf probes in addition to a Pharma Assay Services business which allow customers to run assays for their unique targets rapidly. Since its first launch in 2011, the technology boasts 1200+ citations, a new publication each day now, for single, duplex and multiplex RNA analysis.
ACD’s products and services are based on its proprietary RNAscope® Technology, the first multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity.
In addition to its ongoing efforts to develop proprietary diagnostic tests for cancer management, ACD also establishes partnerships with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development. These internal and external efforts will continue to position ACD as a leader in molecular diagnostics and companion diagnostics.
The company’s technology overcomes critical hurdles in the identification and validation of biomarkers for companion diagnostics. ACD’s RNAscope® platform provides a new way of localizing and measuring RNA in situ with exceptional levels of sensitivity, specificity, and the ability to multiplex. Turnaround time for a new assay is reduced to three weeks. These advantages make the technology a powerful tool to address the issue of patient and disease heterogeneity, thus shortening the path to personalized medicine.
北京美科美生物技术开发有限公司
代理商实名认证
钻石会员
入驻年限：11年
